New Recruiting Trial: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

WHY IT MATTERS

This trial offers metastatic renal cell carcinoma patients access to a novel combination approach that may enhance the effectiveness of existing immunotherapies by incorporating a live biotherapeutic product.

Researchers are testing a new combination treatment for advanced kidney cancer that has spread to other parts of the body. The treatment combines two immunotherapy drugs (nivolumab and ipilimumab) with an experimental live biotherapeutic product called EXL01. This Phase 1 trial is now accepting patients to see if adding EXL01 to the standard immunotherapy improves outcomes.

NCT ID: NCT07128680 Title: Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Status: RECRUITING Phase: PHASE1 Sponsor: City of Hope Medical Center Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07128680 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you have metastatic renal cell carcinoma, visit clinicaltrials.gov/study/NCT07128680 to check eligibility requirements and contact City of Hope Medical Center about enrollment.